Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.13 -3.2%	$2.11	$1.43 ▼ $3.98	$220.90M	1.65	166,751 shs	94,811 shs
ALLO Allogene Therapeutics	$1.07 +2.9%	$1.25	$0.86 ▼ $3.78	$227.48M	0.35	5.42 million shs	8.13 million shs
MNPR Monopar Therapeutics	$35.86 +7.0%	$38.04	$2.15 ▼ $54.30	$206.76M	1.05	22,796 shs	30,434 shs
VHAQ Viveon Health Acquisition	$11.00	$11.00	$0.00 ▼ $12.48	$62.26M	-0.1	12 shs	99 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-3.18%	+2.40%	+3.90%	+24.56%	-35.26%
ALLO Allogene Therapeutics	+2.88%	+1.90%	-13.71%	-3.60%	-52.44%
MNPR Monopar Therapeutics	+7.01%	-10.57%	-9.81%	-3.50%	+1,486.73%
VHAQ Viveon Health Acquisition	0.00%	0.00%	0.00%	0.00%	+10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.0205 of 5 stars	3.5	2.0	0.0	0.0	2.0	0.8	0.6
ALLO Allogene Therapeutics	2.5701 of 5 stars	3.4	2.0	0.0	0.0	2.4	2.5	0.6
MNPR Monopar Therapeutics	2.7987 of 5 stars	3.4	3.0	0.0	0.0	3.3	2.5	0.0
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	463.38% Upside
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	689.20% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	67.32% Upside
VHAQ Viveon Health Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VHAQ, MNPR, ACIU, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.89	N/A	N/A	$0.90 per share	2.37
ALLO Allogene Therapeutics	$20K	11,702.06	N/A	N/A	$2.01 per share	0.53
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-174.94%	-49.35%	-23.16%	N/A
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-53.37%	-41.23%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	8/15/2025 (Estimated)
VHAQ Viveon Health Acquisition	-$610K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VHAQ, MNPR, ACIU, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/5/2025	Q2 2025	ACIU AC Immune	-$0.20	-$0.25	-$0.05	-$0.25	$1.98 million	$1.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.33	1.33
ALLO Allogene Therapeutics	N/A	9.71	9.71
MNPR Monopar Therapeutics	N/A	36.91	36.91
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ALLO Allogene Therapeutics	83.63%
MNPR Monopar Therapeutics	1.83%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ALLO Allogene Therapeutics	13.20%
MNPR Monopar Therapeutics	20.50%
VHAQ Viveon Health Acquisition	75.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.86 million	Not Optionable
VHAQ Viveon Health Acquisition	2	5.66 million	1.40 million	Not Optionable

VHAQ, MNPR, ACIU, and ALLO Headlines

Recent News About These Companies

Viveon Health Acquisition Corp

November 21, 2024 | investing.com

Clearday, Inc. (CLRD)

September 6, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updated

May 3, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success

May 2, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process

February 28, 2024 | finanznachrichten.de

VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS

February 27, 2024 | globenewswire.com

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

February 21, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

December 27, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)

December 22, 2023 | tmcnet.com

San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.

November 13, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)

October 24, 2023 | finance.yahoo.com

VHAQ-R Viveon Health Acquisition Corp.

September 23, 2023 | seekingalpha.com

Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation

September 15, 2023 | marketwatch.com

VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION

September 15, 2023 | finance.yahoo.com

Viveon Healthcare Increases Consideration Offered to Clearday Shareholders

September 5, 2023 | finance.yahoo.com

SPAC Viveon ups merger consideration for Clearday to $500M

August 29, 2023 | msn.com

Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement

August 29, 2023 | finance.yahoo.com

VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING

April 25, 2023 | finance.yahoo.com

Viveon Health Acquisition Corp. (VHAQ-RT)

April 18, 2023 | finance.yahoo.com

(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market

April 12, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VHAQ, MNPR, ACIU, and ALLO Company Descriptions

AC Immune NASDAQ:ACIU

$2.13 -0.07 (-3.18%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.13 0.00 (0.00%)

As of 08/14/2025 04:10 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Allogene Therapeutics NASDAQ:ALLO

$1.07 +0.03 (+2.88%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.00 (+0.47%)

As of 08/14/2025 07:22 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Monopar Therapeutics NASDAQ:MNPR

$35.86 +2.35 (+7.01%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$36.31 +0.45 (+1.25%)

As of 08/14/2025 05:37 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Viveon Health Acquisition NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time